If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Pacira (PCRX)
Pacira (PCRX) beats earnings estimates in the fourth quarter of 2019. Revenues are in line with estimates.
PCRX vs. ZTS: Which Stock Is the Better Value Option?
PCRX vs. ZTS: Which Stock Is the Better Value Option?
Pacira (PCRX) could produce exceptional returns because of its solid growth attributes.
Pacira BioSciences, Inc. (NASDAQ:PCRX) shares fell 3.0% to US$48.49 in the week since its latest annual results...
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
Pacira BioSciences, Inc. (PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on Thursday, May 7, 2020. International callers may dial 1-720-545-0035 and use the same passcode.
Q4 2019 Pacira Biosciences Inc Earnings Call
-- Total revenues increased 16 percent over prior year first quarter ---- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., May 07, 2020 -- Pacira BioSciences, Inc..
Pacira (PCRX) possesses solid growth attributes, which could help it handily outperform the market.
Pacira BioSciences (PCRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
PARSIPPANY, N.J., May 13, 2020 -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the 2020 RBC Capital Markets Global Healthcare Virtual.
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PARSIPPANY, N.J., March 09, 2020 -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the 2020 Barclays Global Healthcare Conference at 9:00 AM ET.
Amid the doom and gloom, we have cherry picked four stocks that possess potential to perform well in the long run.
The Zacks Analyst Blog Highlights: Pacira Pharmaceuticals, Computer Programs and Systems, Mattel and Performance Food Group
In 2007, Dave Stack was appointed CEO of Pacira BioSciences, Inc. (NASDAQ:PCRX). This report will, first, examine the...
Pacira BioSciences, Inc. (PCRX), a leading provider of innovative non-opioid pain management options, today announces the appointment of Donald C. Manning, M.D., Ph.D., as the Company’s Chief Medical Officer, effective immediately. Dr. Manning, who brings more than 20 years of experience in biopharmaceutical executive leadership, was most recently, Chief Medical Officer at Adynxx, Inc., a development company focused on advancing disease-modifying products for the treatment of pain management and inflammation. In his new position, Dr. Manning will report directly to David Stack, chairman and chief executive officer of Pacira BioSciences.
PARSIPPANY, N.J., May 27, 2020 -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the 2020 Jefferies Virtual Healthcare Conference at 9:30 AM ET.